Maria Monica Barzago
Overview
Explore the profile of Maria Monica Barzago including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
296
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Puri S, Gadda A, Polsinelli I, Barzago M, Toto A, Sriramoju M, et al.
J Mol Biol
. 2025 Jan;
437(5):168958.
PMID: 39842712
Light chain (AL) amyloidosis is the most common systemic amyloid disease characterized by abnormal accumulation of amyloid fibrils derived from immunoglobulin light chains (LCs). Both full-length (FL) LCs and their...
2.
Broggini L, Barzago M, Speranzini V, Schulte T, Sonzini F, Giono M, et al.
J Mol Biol
. 2023 Oct;
435(24):168320.
PMID: 37865287
Light chain amyloidosis (AL) is a systemic disease where fibrillar deposition of misfolded immunoglobulin light chains (LCs) severely affects organ function and results in poor prognosis for patients, especially when...
3.
Natale C, Barzago M, Colnaghi L, De Luigi A, Orsini F, Fioriti L, et al.
Int J Mol Sci
. 2022 Oct;
23(19).
PMID: 36232578
A clear relationship between the tau assemblies and toxicity has still to be established. To correlate the tau conformation with its proteotoxic effect in vivo, we developed an innovative cell-worm-based...
4.
Russo R, Romeo M, Schulte T, Maritan M, Oberti L, Barzago M, et al.
Int J Mol Sci
. 2022 Jan;
23(2).
PMID: 35055136
Light chain amyloidosis (AL) is caused by the aberrant overproduction of immunoglobulin light chains (LCs). The resulting abnormally high LC concentrations in blood lead to deposit formation in the heart...
5.
Garofalo M, Piccoli L, Romeo M, Barzago M, Ravasio S, Foglierini M, et al.
Nat Commun
. 2021 Jun;
12(1):3532.
PMID: 34112780
In systemic light chain amyloidosis (AL), pathogenic monoclonal immunoglobulin light chains (LC) form toxic aggregates and amyloid fibrils in target organs. Prompt diagnosis is crucial to avoid permanent organ damage,...
6.
Zanier E, Barzago M, Vegliante G, Romeo M, Restelli E, Bertani I, et al.
Neurobiol Dis
. 2021 Mar;
153:105330.
PMID: 33711491
Traumatic brain injury (TBI) is associated with widespread tau pathology in about 30% of patients surviving late after injury. We previously found that TBI in mice induces the formation of...
7.
Natale C, Barzago M, Diomede L
Brain Sci
. 2020 Nov;
10(11).
PMID: 33187241
The understanding of the genetic, biochemical, and structural determinants underlying tau aggregation is pivotal in the elucidation of the pathogenic process driving tauopathies and the design of effective therapies. Relevant...
8.
Paroni G, Zanetti A, Barzago M, Kurosaki M, Guarrera L, Fratelli M, et al.
Cancers (Basel)
. 2020 Oct;
12(10).
PMID: 33081033
Triple-negative breast cancer () is a heterogeneous disease that lacks effective therapeutic options. In this study, we profile eighteen cell lines for their sensitivity to the anti-proliferative action of all-trans...
9.
Bolis M, Paroni G, Fratelli M, Vallerga A, Guarrera L, Zanetti A, et al.
Cancers (Basel)
. 2020 May;
12(5).
PMID: 32384653
All-trans retinoic acid (ATRA), a recognized differentiating agent, has significant potential in the personalized/stratified treatment of breast cancer. The present study reports on the molecular mechanisms underlying the anti-tumor activity...
10.
Giorgino T, Mattioni D, Hassan A, Milani M, Mastrangelo E, Barbiroli A, et al.
Biochim Biophys Acta Mol Basis Dis
. 2019 Jan;
1865(3):648-660.
PMID: 30625383
AGel amyloidosis, formerly known as familial amyloidosis of the Finnish-type, is caused by pathological aggregation of proteolytic fragments of plasma gelsolin. So far, four mutations in the gelsolin gene have...